Fosamax vs Prolia (Denosumab): Switching Between Them Safely

How Alendronate and Denosumab Work Differently

Alendronate and denosumab both reduce bone resorption, but they do so through distinct mechanisms, and understanding the difference explains why switching direction matters so much.

Alendronate is a nitrogen-containing bisphosphonate. After oral absorption (bioavailability around 0.7%), it binds to hydroxyapatite on bone surfaces and is incorporated into the bone matrix. When osteoclasts resorb bisphosphonate-laden bone, alendronate inhibits farnesyl pyrophosphate synthase inside the cell, triggering osteoclast apoptosis 1. Because the drug becomes embedded in bone mineral, its skeletal half-life extends to roughly 10 years. That prolonged residence time is why alendronate continues to suppress resorption even after a patient stops taking it.

Denosumab is a fully human monoclonal antibody against RANK ligand (RANKL). By binding circulating RANKL, it prevents RANKL from activating the RANK receptor on osteoclast precursors, effectively blocking osteoclast formation and survival 2. The effect is potent but reversible. Once serum denosumab concentrations fall (roughly 5 to 6 months post-injection), osteoclast activity rebounds, often overshooting pre-treatment levels.

This pharmacologic contrast creates an asymmetry: stopping alendronate leaves a residual anti-resorptive effect in bone, while stopping denosumab leaves none. A 2017 analysis in the Journal of Bone and Mineral Research documented that within 12 months of denosumab discontinuation, patients lost all BMD gains at the lumbar spine and some experienced multiple vertebral fractures 3.

Fracture Reduction: Comparing the Landmark Trials

Denosumab produced a larger reduction in vertebral fractures across its key trial, though the two drugs have never been tested head-to-head in a single randomized controlled study designed to compare fracture endpoints.

The FIT trial (Fracture Intervention Trial), published in JAMA in 1998, enrolled 2,027 postmenopausal women with low femoral-neck BMD and at least one vertebral fracture. Over 3 years, alendronate 5 to 10 mg daily reduced the risk of new vertebral fractures by 47% compared with placebo (relative risk 0.53, 95% CI 0.41 to 0.68) 1. Hip fractures declined by 51% in this population.

The FREEDOM trial, published in the New England Journal of Medicine in 2009, enrolled 7,868 postmenopausal women aged 60 to 90 with a T-score between -2.5 and -4.0. Denosumab 60 mg subcutaneously every 6 months reduced vertebral fractures by 68% over 3 years (relative risk 0.32, 95% CI 0.26 to 0.41) and hip fractures by 40% (hazard ratio 0.60, 95% CI 0.37 to 0.97) 2.

Cross-trial comparisons carry limitations. The FREEDOM population was older (mean age 72.3 vs. 68 in FIT) and had somewhat different baseline fracture risks. A network meta-analysis published in Osteoporosis International in 2019 suggested denosumab may offer modestly greater vertebral fracture reduction than oral bisphosphonates, but confidence intervals overlapped 4. No guideline body has declared one agent categorically superior.

The American Association of Clinical Endocrinology (AACE) 2020 guidelines list both alendronate and denosumab as first-line options for postmenopausal osteoporosis, reserving the stronger recommendation for denosumab in patients at very high fracture risk 5.

Switching from Alendronate to Denosumab

This is the easier direction. Patients who plateau on alendronate or cannot tolerate its gastrointestinal side effects often transition to denosumab without a washout period.

The STAND trial (Study of Transitioning from Alendronate to Denosumab), published in the Journal of Clinical Endocrinology & Metabolism, randomized 504 postmenopausal women already on alendronate for at least 6 months to either continue alendronate 70 mg weekly or switch to denosumab 60 mg every 6 months. At 12 months, the denosumab group gained an additional 1.9% BMD at the total hip and 3.0% at the lumbar spine compared with those continuing alendronate 6. Bone turnover markers (serum CTX and P1NP) dropped more rapidly and more deeply in the denosumab arm.

Timing is simple. A patient can receive the first denosumab injection at the time the next alendronate dose would have been due, or shortly thereafter. No bridging agent is needed. The residual bisphosphonate in bone provides a safety net during the transition.

Clinicians switch for several reasons: persistent GI intolerance (esophagitis, reflux, difficulty with the 30-minute upright requirement), inadequate BMD response after 3 to 5 years of alendronate, or patient preference for a twice-yearly injection over a weekly pill.

One consideration: once a patient starts denosumab, an exit strategy should be part of the initial discussion. As the Endocrine Society's 2019 clinical practice guideline on pharmacological management of osteoporosis states, "Clinicians should have a plan for transition when denosumab is discontinued" 7. That exit plan almost always involves a bisphosphonate.

Switching from Denosumab to Alendronate: The Rebound Problem

Going in the opposite direction is where the clinical risk concentrates. Stop denosumab without a bisphosphonate bridge and bone turnover markers can spike above the pre-treatment baseline within 3 to 6 months.

A 2017 case series identified multiple vertebral fractures in patients who discontinued denosumab without follow-on therapy. Bone turnover markers (CTX) rose to 2 to 3 times baseline levels, and some patients sustained 4 or more new vertebral compression fractures within 8 to 16 months of missing a dose 3. The phenomenon occurs because denosumab suppression is fully reversible: once the antibody clears, the pool of osteoclast precursors that had been held in check suddenly differentiates en masse.

The largest prospective study addressing this transition, published in the Journal of Bone and Mineral Research in 2020, showed that a single infusion of zoledronic acid 5 mg given 6 months after the last denosumab injection partially, but not completely, prevented the rebound rise in CTX 8. About 48% of patients still showed CTX levels above pre-treatment baselines at 12 months, suggesting one zoledronate infusion may be insufficient for some individuals.

Oral alendronate is the most commonly used bridge in practice. The DATA-Switch extension (published in the Journal of Clinical Endocrinology & Metabolism) demonstrated that patients who transitioned from denosumab to alendronate 70 mg weekly maintained more BMD at the spine and hip than those who received placebo, though some bone loss still occurred compared with continued denosumab 9.

Timing the Transition

Current expert consensus (Endocrine Society, ASBMR) recommends:

1. Start the oral bisphosphonate approximately 6 months after the last denosumab injection (i.e., when the next denosumab dose would have been due, or no later than 1 month after).
2. Continue alendronate for at least 12 months, with reassessment of bone turnover markers (serum CTX) at 3 and 6 months.
3. If CTX rises above the patient's pre-denosumab baseline, some experts advocate for an additional IV zoledronic acid infusion 10.

Delaying the bisphosphonate by even a few months opens a window of unprotected bone loss. A patient who simply stops denosumab at month 6 and does not start alendronate until month 10 has already lost the critical first weeks of the rebound period.

Who Should Stay on Denosumab Long-Term

Some patients are better served by remaining on denosumab indefinitely rather than attempting a switch.

The FREEDOM Extension trial followed 4,550 women on continuous denosumab for up to 10 years. BMD continued to increase through year 10, reaching cumulative gains of 21.7% at the lumbar spine and 9.2% at the total hip. Fracture incidence remained low and comparable to rates seen in years 1 through 3. Rates of osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) were 5.2 and 0.8 per 10,000 patient-years, respectively 11.

Patients at very high fracture risk, those with T-scores below -3.0, prevalent vertebral fractures, or glucocorticoid-dependent conditions, may face more harm from the rebound of discontinuation than from long-term denosumab exposure. The AACE 2020 guideline specifically recommends continued denosumab in "very high risk" patients rather than switching to a bisphosphonate 5.

Conversely, patients who started denosumab for moderate-risk osteoporosis and have achieved a T-score above -2.0 at the hip and above -2.5 at the spine after several years may be reasonable candidates for a carefully managed transition to oral alendronate with close monitoring of bone turnover markers.

Practical Comparison: Side Effects and Logistics

The side-effect profiles and practical considerations differ enough to influence treatment choice and switching decisions.

Alendronate requires fasting administration with a full glass of water, followed by 30 minutes of remaining upright. Esophageal irritation is the most common complaint, reported in 2 to 3% of patients in clinical trials. Musculoskeletal pain occurs in about 2.6% of users. Long-term use beyond 5 years raises theoretical concern for AFF (incidence roughly 1.78 per 100,000 person-years according to a 2020 meta-analysis) 12. Generic alendronate costs approximately $10 to $30 per month.

Denosumab is administered as a 60 mg subcutaneous injection every 6 months in a clinical setting. The most commonly reported side effects in FREEDOM were back pain (34.7% vs. 34.6% placebo), extremity pain (11.7%), and musculoskeletal pain (7.6%). Hypocalcemia can occur, particularly in patients with vitamin D deficiency or renal impairment. The wholesale acquisition cost of Prolia is approximately $1,800 per injection ($3,600 per year) before insurance, though most commercially insured patients pay significantly less after copay assistance programs 2.

Adherence patterns differ. A retrospective cohort study published in Osteoporosis International found 12-month persistence with denosumab was 81.6% versus 55.3% for oral bisphosphonates, likely driven by the convenience of twice-yearly dosing 13. Poor adherence to oral bisphosphonates is one of the most common reasons clinicians initiate a switch to denosumab.

Monitoring During and After a Switch

Bone turnover markers are the early-warning system for rebound resorption after denosumab discontinuation, and they shift faster than DXA measurements.

Serum CTX (C-terminal telopeptide): The most practical resorption marker. In stable denosumab therapy, CTX is profoundly suppressed (often below assay detection limits). After discontinuation, a rise above 0.6 ng/mL, or above the patient's known pre-treatment value, signals inadequate bisphosphonate coverage 8.

P1NP (procollagen type 1 N-propeptide): A bone formation marker. Its rebound rise typically follows CTX by several weeks and confirms that formation-resorption coupling is accelerating.

DXA scan: Should be performed 12 months after the switch. A decline of more than 3 to 5% at the lumbar spine or hip warrants clinical action, potentially re-initiating denosumab or adding IV zoledronic acid.

Vitamin D levels should be 30 ng/mL or higher before initiating denosumab and before transitioning off it. Calcium intake of 1,000 to 1,200 mg daily (diet plus supplement) should be confirmed at each visit.

Decision Framework: Which Direction, and When

The clinical question is usually not "which drug is better" in isolation but rather "given where this patient is in their treatment course, what should happen next."

Switch to denosumab when: The patient has GI intolerance to alendronate, BMD has plateaued after 3 to 5 years of bisphosphonate therapy, adherence to weekly oral therapy is poor, or the patient's fracture risk is very high and a more potent anti-resorptive is warranted.

Switch to alendronate when: The patient and clinician have decided to discontinue denosumab (for cost, preference, or reassessed risk), the patient has been on denosumab for a defined treatment course and achieved a satisfactory T-score, or the patient cannot continue clinic visits for subcutaneous injections.

Stay on current therapy when: BMD is improving or stable, the patient tolerates the medication, and the fracture risk profile has not changed. The AACE 2020 guidelines advise against routine bisphosphonate "drug holidays" in very-high-risk patients, and the same logic applies to denosumab. If the drug is working and the patient is tolerating it, changing for the sake of change introduces unnecessary risk 5.

Patients on denosumab should have a documented exit strategy from the start of therapy. If a patient begins denosumab at age 65, the question "what happens when we stop" should be answered before the first injection, not five years later.